United States

People: Interleukin Genetics Inc (ILIU.PK)

ILIU.PK on OTC Markets Group

21 Feb 2017
Change (% chg)

$0.01 (+9.70%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Kornman, Kenneth 

Dr. Kenneth S. Kornman Ph.D. DDS is President, Chief Scientific Officer, Director of the Company. He was Chief Executive Officer of Interleukin Genetics, Inc. He was a member of our Board of Directors from August 2006 through April 2010, and in connection with our former Chief Executive Officer’s resignation on August 23, 2012, the Board of Directors appointed Dr. Kornman as a director to fill the vacancy created by the former Chief Executive Officer’s resignation. Prior to founding the Company in 1986, Dr. Kornman was a Department Chairman and Professor at The University of Texas Health Center at San Antonio. He has also been a consultant and scientific advisor for many major oral care and pharmaceutical companies. Dr. Kornman currently holds an academic appointment at Harvard University. He holds multiple patents in the pharmaceutical area, has published three books and more than 125 scientific papers and has lectured and consulted worldwide on the transfer of technology to clinical practice. Dr. Kornman also holds an MS (Periodontics) and Ph.D. (Microbiology-Immunology) from the University of Michigan. Our Board of Directors has concluded that Dr. Kornman should serve as a director because of his prior executive management experience, his scientific expertise and his knowledge of the dental and biotechnology industries. Dr. Kornman has not served on any other public company boards in the past five years.

Basic Compensation

Total Annual Compensation, USD 401,400
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 531,096
Fiscal Year Total, USD 932,496

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --